ARS Pharmaceuticals Reports Quarterly Earnings, Meets Estimates

The biopharmaceutical company develops treatments for severe allergic reactions.

Mar. 9, 2026 at 12:06pm

Got story updates? Submit your updates here. ›

ARS Pharmaceuticals (NASDAQ:SPRY) reported its quarterly earnings results on Monday, posting a loss of $0.42 per share, which met the consensus estimate. The company had revenue of $28.09 million for the quarter, exceeding the $25.58 million expected by analysts. ARS Pharmaceuticals is developing a needle-free, low-dose intranasal epinephrine nasal spray called neffy for the emergency treatment of type I allergic reactions, including anaphylaxis.

Why it matters

ARS Pharmaceuticals' quarterly results provide insight into the company's financial performance and progress in developing its lead product candidate, neffy, which aims to provide a more convenient option for treating severe allergic reactions compared to traditional epinephrine injections.

The details

For the quarter, ARS Pharmaceuticals reported a net loss of $56.06 million, with a negative return on equity of 38.77%. The company's shares opened at $9.06 on Monday, down from a 52-week high of $18.90. ARS Pharmaceuticals is focused on advancing neffy, its needle-free epinephrine nasal spray, through clinical development and regulatory approval.

  • ARS Pharmaceuticals reported its quarterly earnings results on Monday, March 9, 2026.
  • The company's shares opened at $9.06 on the day of the earnings release.

The players

ARS Pharmaceuticals, Inc.

A biopharmaceutical company developing treatments for severe allergic reactions, including a needle-free, low-dose intranasal epinephrine nasal spray called neffy.

Rubric Capital Management LP

An institutional investor that owns 4.5 million shares of ARS Pharmaceuticals, representing a 247.5% increase in its stake.

Millennium Management LLC

An institutional investor that owns a $36.912 million stake in ARS Pharmaceuticals.

Got photos? Submit your photos here. ›

The takeaway

ARS Pharmaceuticals' quarterly results demonstrate the company's progress in advancing its lead product candidate, neffy, which aims to provide a more convenient option for treating severe allergic reactions. The company's financial performance and institutional investor support suggest it is well-positioned to continue its development efforts.